The initial treatment of Parkinson's disease should begin with levodopa
Identifieur interne : 004C24 ( Main/Curation ); précédent : 004C23; suivant : 004C25The initial treatment of Parkinson's disease should begin with levodopa
Auteurs : William J. Weiner [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1999-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Benzothiazoles, Bromocriptine (therapeutic use), Chemotherapy, Dopamine receptor agonists, Drug Therapy, Combination, Early, Essential Tremor (drug therapy), Female, Human, Humans, Indoles (therapeutic use), Levodopa, Levodopa (pharmacology), Levodopa (therapeutic use), Levodopa‐sparing strategies, Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pergolide (therapeutic use), Receptors, Dopamine (drug effects), Thiazoles (therapeutic use), Time Factors, Toxicity, Treatment.
- MESH :
- chemical , drug effects : Receptors, Dopamine.
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Bromocriptine, Indoles, Levodopa, Pergolide, Thiazoles.
- drug therapy : Essential Tremor, Parkinson Disease.
- Aged, Benzothiazoles, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Time Factors.
Abstract
For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long‐term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa‐sparing strategies and levodopa‐induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa‐sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.
Url:
DOI: 10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001686
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001686
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003390
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :007922
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002D67
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :003A57
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002D04
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :007B53
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004138
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :004138
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004087
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000113
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000113
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000113
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :007694
Links to Exploration step
ISTEX:42D0059395A046E21B2586D694C8D0DB5F953E86Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa</title>
<author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:42D0059395A046E21B2586D694C8D0DB5F953E86</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q</idno>
<idno type="url">https://api.istex.fr/document/42D0059395A046E21B2586D694C8D0DB5F953E86/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001686</idno>
<idno type="wicri:Area/Istex/Curation">001686</idno>
<idno type="wicri:Area/Istex/Checkpoint">003390</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Weiner W:the:initial:treatment</idno>
<idno type="wicri:Area/Main/Merge">007922</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:99-0475653</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002D67</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003A57</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002D04</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Weiner W:the:initial:treatment</idno>
<idno type="wicri:Area/Main/Merge">007B53</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10495031</idno>
<idno type="wicri:Area/PubMed/Corpus">004138</idno>
<idno type="wicri:Area/PubMed/Curation">004138</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004087</idno>
<idno type="wicri:Area/Ncbi/Merge">000113</idno>
<idno type="wicri:Area/Ncbi/Curation">000113</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000113</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Weiner W:the:initial:treatment</idno>
<idno type="wicri:Area/Main/Merge">007694</idno>
<idno type="wicri:Area/Main/Curation">004C24</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa</title>
<author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Miami School of Medicine, Miami, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="1999-09">1999-09</date>
<biblScope unit="vol">14</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="716">716</biblScope>
<biblScope unit="page" to="724">724</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">42D0059395A046E21B2586D694C8D0DB5F953E86</idno>
<idno type="DOI">10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q</idno>
<idno type="ArticleID">MDS1002</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Benzothiazoles</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Dopamine receptor agonists</term>
<term>Drug Therapy, Combination</term>
<term>Early</term>
<term>Essential Tremor (drug therapy)</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Indoles (therapeutic use)</term>
<term>Levodopa</term>
<term>Levodopa (pharmacology)</term>
<term>Levodopa (therapeutic use)</term>
<term>Levodopa‐sparing strategies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Pergolide (therapeutic use)</term>
<term>Receptors, Dopamine (drug effects)</term>
<term>Thiazoles (therapeutic use)</term>
<term>Time Factors</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Bromocriptine</term>
<term>Indoles</term>
<term>Levodopa</term>
<term>Pergolide</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Essential Tremor</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Benzothiazoles</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Précoce</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long‐term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa‐sparing strategies and levodopa‐induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa‐sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.</div>
</front>
</TEI>
<double idat="0885-3185:1999:Weiner W:the:initial:treatment"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The initial treatment of Parkinson's disease should begin with levodopa</title>
<author><name sortKey="Weiner, W J" sort="Weiner, W J" uniqKey="Weiner W" first="W. J." last="Weiner">W. J. Weiner</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Miami School of Medicine</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0475653</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0475653 INIST</idno>
<idno type="RBID">Pascal:99-0475653</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002D67</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003A57</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002D04</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Weiner W:the:initial:treatment</idno>
<idno type="wicri:Area/Main/Merge">007B53</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The initial treatment of Parkinson's disease should begin with levodopa</title>
<author><name sortKey="Weiner, W J" sort="Weiner, W J" uniqKey="Weiner W" first="W. J." last="Weiner">W. J. Weiner</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Miami School of Medicine</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Early</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Précoce</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa</title>
<author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:42D0059395A046E21B2586D694C8D0DB5F953E86</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q</idno>
<idno type="url">https://api.istex.fr/document/42D0059395A046E21B2586D694C8D0DB5F953E86/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001686</idno>
<idno type="wicri:Area/Istex/Curation">001686</idno>
<idno type="wicri:Area/Istex/Checkpoint">003390</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Weiner W:the:initial:treatment</idno>
<idno type="wicri:Area/Main/Merge">007922</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa</title>
<author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Miami School of Medicine, Miami, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="1999-09">1999-09</date>
<biblScope unit="vol">14</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="716">716</biblScope>
<biblScope unit="page" to="724">724</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">42D0059395A046E21B2586D694C8D0DB5F953E86</idno>
<idno type="DOI">10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q</idno>
<idno type="ArticleID">MDS1002</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine receptor agonists</term>
<term>Levodopa</term>
<term>Levodopa‐sparing strategies</term>
<term>Parkinson's disease</term>
<term>Toxicity</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long‐term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa‐sparing strategies and levodopa‐induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa‐sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa.</title>
<author><name sortKey="Weiner, W J" sort="Weiner, W J" uniqKey="Weiner W" first="W J" last="Weiner">W J Weiner</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Miami School of Medicine, Florida 33136, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Miami School of Medicine, Florida 33136</wicri:regionArea>
<wicri:noRegion>Florida 33136</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10495031</idno>
<idno type="pmid">10495031</idno>
<idno type="wicri:Area/PubMed/Corpus">004138</idno>
<idno type="wicri:Area/PubMed/Curation">004138</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004087</idno>
<idno type="wicri:Area/Ncbi/Merge">000113</idno>
<idno type="wicri:Area/Ncbi/Curation">000113</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000113</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Weiner W:the:initial:treatment</idno>
<idno type="wicri:Area/Main/Merge">007694</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa.</title>
<author><name sortKey="Weiner, W J" sort="Weiner, W J" uniqKey="Weiner W" first="W J" last="Weiner">W J Weiner</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Miami School of Medicine, Florida 33136, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Miami School of Medicine, Florida 33136</wicri:regionArea>
<wicri:noRegion>Florida 33136</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Benzothiazoles</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Essential Tremor (drug therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Indoles (therapeutic use)</term>
<term>Levodopa (pharmacology)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Pergolide (therapeutic use)</term>
<term>Receptors, Dopamine (drug effects)</term>
<term>Thiazoles (therapeutic use)</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Bromocriptine</term>
<term>Indoles</term>
<term>Levodopa</term>
<term>Pergolide</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Essential Tremor</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Benzothiazoles</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long-term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa-sparing strategies and levodopa-induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa-sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 004C24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:42D0059395A046E21B2586D694C8D0DB5F953E86 |texte= The initial treatment of Parkinson's disease should begin with levodopa }}
This area was generated with Dilib version V0.6.23. |